Payment overview · 2025
General Payments
$66.23
3 reported records · 2 companies
Healthcare provider profile · identity verified
Kim M Brew, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · JACKSONVILLE, FL · NPI 1316245418
Verified facts
What the public records show
CMS Open Payments records show Kim M Brew, ARNP received $66.23 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 59.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.15 | 59.1% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $27.08 | 40.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $66.23 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.15 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.15 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.15 | 2 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $27.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 418 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 365 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 281 | 79 |
| Lisinopril | Lisinopril | 263 | 107 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 215 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 61 |
| Gabapentin | Gabapentin | 177 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 56 |
| Losartan Potassium | Losartan Potassium | 165 | 63 |
| Metformin Hcl | Metformin Hcl | 145 | 53 |
| Omeprazole | Omeprazole | 140 | 55 |
| Sertraline Hcl | Sertraline Hcl | 127 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 41 |
| Valsartan | Valsartan | 100 | 41 |
| Alendronate Sodium | Alendronate Sodium | 98 | 33 |
| Furosemide | Furosemide | 97 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 33 |
| Potassium Chloride | Potassium Chloride | 85 | 35 |
| Trazodone Hcl | Trazodone Hcl | 85 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 31 |
| Carvedilol | Carvedilol | 75 | 34 |
| Alprazolam | Alprazolam | 72 | 22 |
| Ozempic | Semaglutide | 72 | 15 |
| Meloxicam | Meloxicam | 69 | 21 |
| Azithromycin | Azithromycin | 67 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 27 |
| Tramadol Hcl | Tramadol Hcl | 66 | 37 |
| Eliquis | Apixaban | 63 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 52 |
| Montelukast Sodium | Montelukast Sodium | 59 | 27 |
| Ezetimibe | Ezetimibe | 53 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 21 |
| Prednisone | Prednisone | 50 | 35 |
| Meclizine Hcl | Meclizine Hcl | 49 | 17 |
| Januvia | Sitagliptin Phosphate | 47 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 37 |
| Pregabalin | Pregabalin | 44 | suppressed |
| Baclofen | Baclofen | 42 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 14 |
| Buspirone Hcl | Buspirone Hcl | 39 | 11 |
| Simvastatin | Simvastatin | 39 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 16 |
| Allopurinol | Allopurinol | 37 | 16 |
| Jardiance | Empagliflozin | 36 | 12 |
| Famotidine | Famotidine | 35 | 15 |
| Ibuprofen | Ibuprofen | 35 | 15 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 15 |
| Primidone | Primidone | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 16 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 11 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | 13 |
| Fluconazole | Fluconazole | 28 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 14 |
| Glipizide | Glipizide | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | 13 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $66.23 · 3 records | PFIZER INC. | ABRYSVO, COMIRNATY, Extended Holter, PREVNAR 20 | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error